We are developing and implementing novel applications of knowledge representation, ontology development and natural language processing to address issues within the pharmaceutical industry. It is well-documented that the pharmaceutical industry is experiencing significant difficulties in maintaining its historical record of drug approvals and financial achievement because of failures in moving compounds from the discovery pipeline to regulatory approval and commercial success. The critical link in this transition is the clinical trial, heavily regulated and monitored for patient safety and drug efficacy. At present, only about 9% of drugs entering clinical trials succeed in being approved by the regulatory bodies, and unfortunately, that, alone, does not guarantee commercial success as a significant number of approved drugs fail upon introduction into the marketplace. Our approach evaluates and refines the hypothesis upon which these trials are based, establishes a comprehensive approach to an early go/no go decision, identifies risk and improves the probability for success.

Hypothesis Generation and Evaluation in Clinical Trial Design

Sabrina Molinaro
2011

Abstract

We are developing and implementing novel applications of knowledge representation, ontology development and natural language processing to address issues within the pharmaceutical industry. It is well-documented that the pharmaceutical industry is experiencing significant difficulties in maintaining its historical record of drug approvals and financial achievement because of failures in moving compounds from the discovery pipeline to regulatory approval and commercial success. The critical link in this transition is the clinical trial, heavily regulated and monitored for patient safety and drug efficacy. At present, only about 9% of drugs entering clinical trials succeed in being approved by the regulatory bodies, and unfortunately, that, alone, does not guarantee commercial success as a significant number of approved drugs fail upon introduction into the marketplace. Our approach evaluates and refines the hypothesis upon which these trials are based, establishes a comprehensive approach to an early go/no go decision, identifies risk and improves the probability for success.
2011
Istituto di Fisiologia Clinica - IFC
Inglese
Meaningful use of complex medical data : acquiring, analyzing and sharing : August 26 -28, 2011
2011 IEEE International Conference on Bioinformatics and Biomedicine, BIBM 2011
26
26
26-28 August 2011
Los Angeles, California
clinical t
healthcare
clinical trials
ID_PUMA: cnr.ifc/2011-A2-009
2
info:eu-repo/semantics/conferenceObject
restricted
274
04 Contributo in convegno::04.02 Abstract in Atti di convegno
Liebman, Michael; Molinaro, Sabrina
File in questo prodotto:
File Dimensione Formato  
prod_201459-doc_44447.pdf

solo utenti autorizzati

Descrizione: Paper
Dimensione 368.27 kB
Formato Adobe PDF
368.27 kB Adobe PDF   Visualizza/Apri   Richiedi una copia

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/20.500.14243/10334
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus ND
  • ???jsp.display-item.citation.isi??? ND
social impact